Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Rep ; 42(4): 112344, 2023 04 25.
Article in English | MEDLINE | ID: mdl-37018073

ABSTRACT

Pre-clinical studies of fragile X syndrome (FXS) have focused on neurons, with the role of glia remaining largely underexplored. We examined the astrocytic regulation of aberrant firing of FXS neurons derived from human pluripotent stem cells. Human FXS cortical neurons, co-cultured with human FXS astrocytes, fired frequent short-duration spontaneous bursts of action potentials compared with less frequent, longer-duration bursts of control neurons co-cultured with control astrocytes. Intriguingly, bursts fired by FXS neurons co-cultured with control astrocytes are indistinguishable from control neurons. Conversely, control neurons exhibit aberrant firing in the presence of FXS astrocytes. Thus, the astrocyte genotype determines the neuronal firing phenotype. Strikingly, astrocytic-conditioned medium, and not the physical presence of astrocytes, is capable of determining the firing phenotype. The mechanistic basis of this effect indicates that the astroglial-derived protein, S100ß, restores normal firing by reversing the suppression of a persistent sodium current in FXS neurons.


Subject(s)
Fragile X Syndrome , Humans , Fragile X Syndrome/genetics , Astrocytes/metabolism , Fragile X Mental Retardation Protein/metabolism , Neurons/metabolism , Coculture Techniques
2.
Mol Autism ; 11(1): 52, 2020 06 19.
Article in English | MEDLINE | ID: mdl-32560741

ABSTRACT

BACKGROUND: Fragile X syndrome (FXS), a neurodevelopmental disorder, is a leading monogenetic cause of intellectual disability and autism spectrum disorder. Notwithstanding the extensive studies using rodent and other pre-clinical models of FXS, which have provided detailed mechanistic insights into the pathophysiology of this disorder, it is only relatively recently that human stem cell-derived neurons have been employed as a model system to further our understanding of the pathophysiological events that may underlie FXS. Our study assesses the physiological properties of human pluripotent stem cell-derived cortical neurons lacking fragile X mental retardation protein (FMRP). METHODS: Electrophysiological whole-cell voltage- and current-clamp recordings were performed on two control and three FXS patient lines of human cortical neurons derived from induced pluripotent stem cells. In addition, we also describe the properties of an isogenic pair of lines in one of which FMR1 gene expression has been silenced. RESULTS: Neurons lacking FMRP displayed bursts of spontaneous action potential firing that were more frequent but shorter in duration compared to those recorded from neurons expressing FMRP. Inhibition of large conductance Ca2+-activated K+ currents and the persistent Na+ current in control neurons phenocopies action potential bursting observed in neurons lacking FMRP, while in neurons lacking FMRP pharmacological potentiation of voltage-dependent Na+ channels phenocopies action potential bursting observed in control neurons. Notwithstanding the changes in spontaneous action potential firing, we did not observe any differences in the intrinsic properties of neurons in any of the lines examined. Moreover, we did not detect any differences in the properties of miniature excitatory postsynaptic currents in any of the lines. CONCLUSIONS: Pharmacological manipulations can alter the action potential burst profiles in both control and FMRP-null human cortical neurons, making them appear like their genetic counterpart. Our studies indicate that FMRP targets that have been found in rodent models of FXS are also potential targets in a human-based model system, and we suggest potential mechanisms by which activity is altered.


Subject(s)
Action Potentials/physiology , Cerebral Cortex/pathology , Fragile X Mental Retardation Protein/metabolism , Induced Pluripotent Stem Cells/pathology , Neurons/pathology , Action Potentials/drug effects , Adolescent , Animals , Cell Differentiation/drug effects , Child, Preschool , Humans , Indoles/pharmacology , Induced Pluripotent Stem Cells/drug effects , Male , Mice , Neurons/drug effects , Riluzole/pharmacology , Sodium Channels/metabolism , Veratridine/pharmacology , Young Adult
3.
Indian J Pathol Microbiol ; 61(3): 418-420, 2018.
Article in English | MEDLINE | ID: mdl-30004070

ABSTRACT

Pulmonary alveolar proteinosis (PAP) - an unusual diffuse lung disease characterized by alveolar accumulation of phospholipoprotein material, with a peak incidence in third to fourth decade and male predominance is also described in children. Recorded prevalence is 0.1/100,000 individuals. Major clinicopathogenetic subtypes include autoimmune (idiopathic) associated with granulocyte-macrophage colony-stimulating factor autoantibodies, secondary form, and the congenital form (associated with surfactant gene mutations). Common presenting features include dyspnea, cough, low-grade fever, inspiratory crackles, and digital clubbing. Pulmonary function shows a restrictive ventilatory defect. X-rays show bilateral patchy to extensive consolidations, and bronchial lavage yields a milky fluid. Characteristic microscopic findings on lung biopsy include filling of terminal bronchioles and alveolar spaces by deep pink granular PAS-positive material. Whole lung lavage is the safest and most effective form of treatment. We present brief profiles of two young children identified as having PAP, along with follow-up data on one of them.


Subject(s)
Lung/pathology , Pulmonary Alveolar Proteinosis/diagnosis , Autoantibodies , Biopsy , Bronchoalveolar Lavage/methods , Bronchoalveolar Lavage Fluid , Child, Preschool , Dyspnea/etiology , Female , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Humans , India/epidemiology , Infant , Lung/cytology , Lung/diagnostic imaging , Male , Prevalence , Pulmonary Alveolar Proteinosis/epidemiology , Pulmonary Alveolar Proteinosis/pathology , Pulmonary Alveolar Proteinosis/therapy , Radiography , Respiratory Insufficiency
SELECTION OF CITATIONS
SEARCH DETAIL
...